{"id":7612,"date":"2019-05-06T06:15:13","date_gmt":"2019-05-06T06:15:13","guid":{"rendered":"https:\/\/www.nicox.com\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\/"},"modified":"2019-05-06T06:15:13","modified_gmt":"2019-05-06T06:15:13","slug":"presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\/","title":{"rendered":"Pr\u00e9sentation sur l\u2019\u00e9tude clinique de phase 2 pour le NCX 470 par le Dr. Thomas Walters \u00e0 la conf\u00e9rence ASCRS 2019"},"content":{"rendered":"<ul>\n<li><strong>Recrutement des patients d\u00e9sormais de 90%<\/strong><\/li>\n<li><strong>Potentiel du NCX 470 pour la r\u00e9duction de la pression intraoculaire (PIO) confirm\u00e9 par un leader d\u2019opinion scientifique dans le domaine de l\u2019ophtalmologie<\/strong><\/li>\n<\/ul>\n<p>Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que le Dr. Thomas Walters, leader d\u2019opinion scientifique dans le domaine de l\u2019ophtalmologie et investigateur clinique dans l\u2019\u00e9tude de phase 2 en cours pour le NCX 470, a fait une pr\u00e9sentation \u00e0 la r\u00e9union annuelle de l\u2019American Society of Cataract and Retinal Surgery (ASCRS) 2019 \u00e0 San Diego, Etats-Unis, montrant les progr\u00e8s dans l\u2019\u00e9tude clinique de phase 2 pour le NCX 470 chez les patients atteints de glaucome ou d\u2019hypertension oculaire.<\/p>\n<p>La pr\u00e9sentation a soulign\u00e9 d\u2019une part, les progr\u00e8s dans l\u2019avancement de cette \u00e9tude portant sur 420 patients, initi\u00e9e en ao\u00fbt 2018, dont le taux de recrutement atteint d\u00e9sormais 90% et d\u2019autre part, le potentiel du NCX 470 \u00e0 devenir l\u2019une des meilleures th\u00e9rapies de premi\u00e8re ligne de sa classe pour la r\u00e9duction de la PIO chez les patients atteints de glaucome ou d\u2019hypertension oculaire.<\/p>\n<p>Le NCX 470 est un nouvel analogue de prostaglandine donneur d\u2019oxyde nitrique (NO) de deuxi\u00e8me g\u00e9n\u00e9ration pour lequel une \u00e9tude clinique de phase 2 multicentrique est en cours aux Etats-Unis pour la r\u00e9duction de la PIO chez les patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire. Les premiers r\u00e9sultats de cette \u00e9tude sont attendus au cours du quatri\u00e8me trimestre de cette ann\u00e9e.<\/p>\n<p>L\u2019ASCRS 2019 s\u2019est tenu du 3 au 7 mai 2019 \u00e0 San Diego, Etats-Unis.<\/p>\n<p>La pr\u00e9sentation s\u2019intitulait <em>\u00ab\u00a0Site Initiation Rates and Subject Enrollment Rates for 28-Day, First-in-Human Phase 2 Clinical Study of NCX 470: Novel NO-Donating Bimatoprost Analog.\u00a0\u00bb<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Recrutement des patients d\u00e9sormais de 90% Potentiel du NCX 470 pour la r\u00e9duction de la pression intraoculaire (PIO) confirm\u00e9 par un leader d\u2019opinion scientifique dans le domaine de l\u2019ophtalmologie Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que le Dr. Thomas Walters, leader d\u2019opinion scientifique dans le [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7612","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pr\u00e9sentation sur l\u2019\u00e9tude clinique de phase 2 pour le NCX 470 par le Dr. Thomas Walters \u00e0 la conf\u00e9rence ASCRS 2019 - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pr\u00e9sentation sur l\u2019\u00e9tude clinique de phase 2 pour le NCX 470 par le Dr. Thomas Walters \u00e0 la conf\u00e9rence ASCRS 2019 - Nicox\" \/>\n<meta property=\"og:description\" content=\"Recrutement des patients d\u00e9sormais de 90% Potentiel du NCX 470 pour la r\u00e9duction de la pression intraoculaire (PIO) confirm\u00e9 par un leader d\u2019opinion scientifique dans le domaine de l\u2019ophtalmologie Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que le Dr. Thomas Walters, leader d\u2019opinion scientifique dans le [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-06T06:15:13+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Pr\u00e9sentation sur l\u2019\u00e9tude clinique de phase 2 pour le NCX 470 par le Dr. Thomas Walters \u00e0 la conf\u00e9rence ASCRS 2019\",\"datePublished\":\"2019-05-06T06:15:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\\\/\"},\"wordCount\":321,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\\\/\",\"name\":\"Pr\u00e9sentation sur l\u2019\u00e9tude clinique de phase 2 pour le NCX 470 par le Dr. Thomas Walters \u00e0 la conf\u00e9rence ASCRS 2019 - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2019-05-06T06:15:13+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pr\u00e9sentation sur l\u2019\u00e9tude clinique de phase 2 pour le NCX 470 par le Dr. Thomas Walters \u00e0 la conf\u00e9rence ASCRS 2019 - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\/","og_locale":"fr_FR","og_type":"article","og_title":"Pr\u00e9sentation sur l\u2019\u00e9tude clinique de phase 2 pour le NCX 470 par le Dr. Thomas Walters \u00e0 la conf\u00e9rence ASCRS 2019 - Nicox","og_description":"Recrutement des patients d\u00e9sormais de 90% Potentiel du NCX 470 pour la r\u00e9duction de la pression intraoculaire (PIO) confirm\u00e9 par un leader d\u2019opinion scientifique dans le domaine de l\u2019ophtalmologie Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que le Dr. Thomas Walters, leader d\u2019opinion scientifique dans le [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\/","og_site_name":"Nicox","article_published_time":"2019-05-06T06:15:13+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\/"},"author":{"name":"","@id":""},"headline":"Pr\u00e9sentation sur l\u2019\u00e9tude clinique de phase 2 pour le NCX 470 par le Dr. Thomas Walters \u00e0 la conf\u00e9rence ASCRS 2019","datePublished":"2019-05-06T06:15:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\/"},"wordCount":321,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\/","url":"https:\/\/www.nicox.com\/fr\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\/","name":"Pr\u00e9sentation sur l\u2019\u00e9tude clinique de phase 2 pour le NCX 470 par le Dr. Thomas Walters \u00e0 la conf\u00e9rence ASCRS 2019 - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2019-05-06T06:15:13+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/presentation-sur-letude-clinique-de-phase-2-pour-le-ncx-470-par-le-dr-thomas-walters-a-la-conference-ascrs-2019\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7612"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7612\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}